Journal
DRUG DISCOVERY TODAY
Volume 6, Issue 22, Pages 1165-1170Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1359-6446(01)02014-1
Keywords
-
Categories
Ask authors/readers for more resources
Drug-disease models and clinical trial simulations are increasingly being used to support trial design and treatment optimization decisions. Less widely recognized is their potential for guiding strategic development decisions. These decisions require economic valuation of the potential product profile of efficacy, safety, ease of use, and so on. This review presents a disguised case study that uses drug-disease modelling to generate a probabilistic forecast of a drug's profile. This allows a quantitative analysis of whether to pursue a once-a-day regimen for an antiretroviral being tested twice-a-day in Phase II trials, and if so, at what dose and for which market segments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available